Archive for the 'Pleural Effusion' Category
An abnormal accumulation of fluid in the pleural space.
May 21st, 2008. Human Tumor-Derived Exosomes Down-Modulate NKG2D Expression
This hyporesponsiveness was evident even in the presence of IL-15, a strong inducer of NKG2D. Our data show that NKG2D is a likely physiological target for exosome-mediated immune evasion in cancer.
May 2nd, 2008. Management of Malignant Pleural Effusion Associated with Trapped Lung Syndrome
Median survival was 126 days (range, 10–175 days). We conclude that long-term placement of a pleural catheter provides effective palliation for malignant pleural effusion associated with trapped lung syndrome.
April 4th, 2008. Establishment of three novel human malignant pleural mesothelioma cell lines: morphological and cytogenetical studies and EGFR mutation status
Conclusion: FACS analysis is more sensitive for evaluating mesothelin expression than immunohistochemistry of cut specimens. Irrespective of the expression of EGFR on FACS analysis, no EGFR mutation was detected. These three cell lines may be useful for studying cellular, molecular and genetic aspects of mesothelioma.
March 25th, 2008. Malignant pleural mesothelioma: Computed tomography and correlation with histology
Conclusions: Ipsilateral volume loss is most frequently associated with sarcomatous or mixed mesothelioma. The remaining imaging findings are not helpful in predicting the histological subtype of malignant mesothelioma.
Posted in Biphasic or Mixed, CT or CAT scan, Diagnosis & Differentiation, Epithelioid, Full Archive, Pleural, Pleural Effusion, Sarcomatoid, Symptoms & Symptom Management, Type of Assessment:, Type of Mesothelioma: | No Comments »
March 15th, 2008. Malignant pleural effusion
Video Assisted Thoracoscopy (VATS) is a safe and well tolerated technique, a complication rate is lower than 0. 5%, VATS can be used to obtain diagnosis and to treat patients with malignant pleural effusion and better expectation of life.
March 8th, 2008. Improved identification of malignant cells in serous effusions using a small, robust panel of antibodies on paraffin-embedded cell suspensions
Conclusion: Immunocytochemical staining of standardized cell block reparations of serous fluid cells with a small panel of 4 antibodies significantly improves diagnostic results compared to cytomorphologic evaluation alone.
January 19th, 2008. Tissue inhibitor of metalloproteinase 2 (TIMP-2) expression in adenocarcinoma pleural effusions
0%. In conclusion, immunocytochemical detection of TIMP-2 could be considered an interesting marker in metastatic adenocarcinoma pleural effusions, and could possibly be used as a component of an antibody panel in diagnostic cytopathology.
January 3rd, 2008. Aberrant splicing and protease involvement in mesothelin release from epithelioid mesothelioma cells
In addition, a splice variant transcript of mesothelin (variant 3) was detected in these MPM cell lines, in accordance with the release of a secreted part of the protein. Our results indicate that both mechanisms could be implicated in soluble mesothelin production by epithelioid mesothelioma cells.
December 25th, 2007. Soluble Mesothelin-Related Peptide Level Elevation in Mesothelioma Serum and Pleural Effusions
Conclusions: These data support SMRP as a promising marker for MPM in both serum and pleural effusion fluid, and justify prospective screening studies of SMRP in combination with other markers for screening of asbestos-exposed cohorts.
December 8th, 2007. Utility of WT-1, p63, MOC31, mesothelin, and cytokeratin (K903 and CK5/6) immunostains in differentiating adenocarcinoma, squamous cell carcinoma, and malignant mesothelioma in effusions
A negative stain with MOC31 can exclude lung ADC. Mesothelin, on the other hand, is not useful in the differential diagnosis of ADC, SCC, and MM.
December 7th, 2007. Renal cell carcinoma with malignant pleural mesothelioma after asbestos exposure: a case report
The incidence is rising in industrialized countries, with the peak expected in the year 2020. However, renal cell carcinoma with malignant pleural mesothelioma is very rare and this is the 2nd case in the Japanese literature.
Posted in Case Study, Causation, Chemotherapy, CT or CAT scan, Diagnosis & Differentiation, Epidemiological, Extrapleural Pneumonectomy (EPP), Full Archive, Occupational Asbestos Exposure, Pleural, Pleural Effusion, Radiation, Surgery, Symptoms & Symptom Management, Treatment, Trimodality Therapy, Type of Assessment:, Type of Mesothelioma: | No Comments »
October 24th, 2007. Increased pleural fluid adenosine deaminase levels in patients with malignant pleural effusions: a potential predictor of talc pleurodesis outcome
These results indicate that Pf-ADA levels could be considered predictors of the outcome of pleurodesis, especially in patient with MM. Furthermore, the present study also demonstrated that Pf-ADA level is a superior test to predict the outcome of pleurodesis compared to pleural fluid pH and albumin level.
October 16th, 2007. Non-invasive diagnosis of pleural malignancies: The role of tumour markers
Conclusions: By using two serum markers (CEA and SMRP) we were able to discriminate mesothelioma from NSCLC with high sensitivity, while Cyfra 21.1 is useful in the discrimination of normal versus malignancy.
October 11th, 2007. Role of DNA microarrays in the diagnosis of pleural exudates: a feasibility study
Conclusions: Gene expression study of cells from pleural fluid is feasible but remains difficult, essentially in relationship with RNA weakness.
October 6th, 2007. The value of calretinin and cytokeratin 5/6 as markers for mesothelioma in cell block preparations of serous effusions
Conclusions: The results confirm that calretinin and CK 5/6 are useful markers for mesothelioma in effusion specimens. CK5/6 staining may be less useful for peritoneal fluid specimens where metastatic adenocarcinomas may be more likely to express the antigen. Further study of ascitic/peritoneal specimens is warranted. However, positive staining, particularly for both antigens, is highly indicative of a mesothelial origin for cells. The two markers make a useful addition to EMA and the panel of adenocarcinoma markers routinely applied to effusion specimens.
September 4th, 2007. Clinical utility of thoracoscopy under local anesthesia
In case of the pneumothorax, treatment with bulla looping or cauterization may be possible, but we do not treat pneumothorax with medical thoracoscopy because it is impossible to approach and find air leaks of lesions located in or near blind spots such as the apex or mediastinal part In case of acute emphysema, it is important to release adhesions and perform effective drainage using thoracoscopy as soon as possible since deposition of fibrin tends to form quickly compartments that make drainage difficult. Since medical thoracoscopy under local anesthesia is rapid, easy, safe, and well-tolerated procedure with an excellent diagnostic yield, it is recommended as a diagnostic procedure for cases with pleural diseases.
August 19th, 2007. Flow cytometric immunophenotyping of cancer cells in effusion specimens: diagnostic and research applications
Our data suggest that FCM is an effective method for the characterization of cancer cells in clinical effusion specimens in both the diagnostic and research setting, and that this method is comparable to immunohistochemistry in terms of sensitivity and specificity, with the additional advantage of providing quantitative data. This review discusses previous work in this area and the future potential of this method in the characterization of tumor cells in serous effusions.
August 3rd, 2007. A Phase I Clinical Trial of Single-Dose Intrapleural IFN-ß Gene Transfer for Malignant Pleural Mesothelioma and Metastatic Pleural Effusions: High Rate of Antitumor Immune Responses
Conclusions: Intrapleural instillation of Ad.IFN-ß is a potentially useful approach for the generation of antitumor immune responses in MPM and MPE patients and should be investigated further for overall clinical efficacy.
Posted in CT or CAT scan, Determining Efficacy, Diagnosis & Differentiation, Full Archive, Gene Therapy, PET Scan, Pleural, Pleural Effusion, Symptoms & Symptom Management, Treatment, Type of Assessment:, Type of Mesothelioma: | No Comments »
June 23rd, 2007. Management of malignant pleural effusion
PET imaging could be of major interest in the diagnosis of mesothelioma and prognosis evaluation. Mesothelioma prognosis has recently been modified by the association of cisplatin with pemetrexed, a new antimetabolite agent, but mesothelioma remains seldom curable.
Posted in Chemotherapy, Cisplatin (Platinol ®), Diagnosis & Differentiation, Full Archive, Immunohistochemistry or IHC, Pemetrexed (Alimta), PET Scan, Pleural, Pleural Effusion, Symptoms & Symptom Management, thoracoscopy, Treatment, Type of Assessment:, Type of Mesothelioma: | No Comments »
June 22nd, 2007. The Diagnostic Role of Claudins in Serous Effusions
Our data suggest that expression of claudin-3 or claudin-7 is specific for adenocarcinoma and rules out the diagnosis of cells as mesothelial and that absence of claudin-1 expression excludes ovarian carcinoma as the possible origin of metastatic adenocarcinoma. Claudins may, therefore, be of diagnostic value in effusion cytology.
|
|  |
